Class of Stock [Axis]
Common Stock, par value $0.0001 per share
Warrants, each exercisable for one share of common stock
Related and Nonrelated Parties [Axis]
Related Party [Member]
Series A Convertible Preferred Stock [Member]
Equity Components [Axis]
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Securities Purchase Agreement [Member]
Purchase Agreement [Member]
Statistical Measurement [Axis]
Maximum [Member]
Geographical [Axis]
UNITED STATES
CANADA
International [Member]
Sale of Stock [Axis]
IPO [Member]
Private Placement [Member]
Parent [Member]
Class of Stock [Axis]
Common Stock Issued to Existing Aspire Biopharma Inc Shareholders [Member]
Conversion Ratio [Member]
Consolidated Entities [Axis]
Parent Company [Member]
Common Stock Obligation Shares Issued [Member]
Loan and Transfer Agreement [Member]
Sponsor and Ssvk Associates Llc [Member]
Apogee Pharma [Member]
Jinal Sheth [Member]
Second Loan And Transfer Agreementt [Member]
Apogee Pharma Two [Member]
First Subscription Agreement [Member]
Second Subscription Agreements [Member]
First and Second Subscription Agreement [Member]
Modified Promissory Note Fee Agreement [Member]
Sponsor [Member]
Affiliates [Member]
Award Date [Axis]
September 27, 2024 [Member]
December 31, 2024 [Member]
Debt Instrument [Axis]
Legal Entity [Axis]
Cobra Alternative Capital Strategies LLC [Member]
August Securities Purchase Agreement [Member]
Award Type [Axis]
August 2025 Securities Purchase Agreement [Member]
First Tranche [Member]
Second Tranche [Member]
Third Tranche [Member]
August 2025 Notes [Member]
Debentures [Member]
Warrant [Member]
Private Placement Warrants [Member]
Second ELOC Agreement [Member]
Arena Business Solutions Global SPC II Ltd [Member]
Business Combination [Axis]
Instaprin Pharmaceuticals Inc [Member]
Title and Position [Axis]
Chief Executive [Member]
Credit Facility [Axis]
Aspire Credit Facility [Member]
Driver Controls Systems Business Unit [Member]
Series A Preferred Stock [Member]
Common Class A [Member]
Class of Warrant or Right [Axis]
Public Warrants [Member]
Corporate Advisory Agreement [Member]
Aspire Biopharma Warrants [Member]
Settlement Agreement [Member]
Convertible Notes [Member]
Investor [Member]
Share Purchase Agreement [Member]
Exchange Agreements [Member]
Measurement Frequency [Axis]
Fair Value, Recurring [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Short-Term Debt, Type [Axis]
Convertible Notes Payable [Member]
Measurement Input Type [Axis]
Measurement Input, Expected Term [Member]
Measurement Input, Share Price [Member]
Measurement Input, Risk Free Interest Rate [Member]
Minimum [Member]
Measurement Input Likelihood [Member]
Liability Class [Axis]
Derivative Financial Instruments, Liabilities [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Note Purchase Agreement [Member]
Management Services Agreement [Member]
Statement [Table]
Statement [Line Items]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Assets
Current assets
Cash and cash equivalents
Prepaid expenses and other current assets
Inventories
Total current assets
Deferred financing costs
Total assets
Liabilities and stockholders’ equity (deficit)
Current liabilities
Accounts payable
Accrued expenses
Due to affiliate
Notes payable – related party
Promissory note fee – related party
Derivative liability
Loan and transfer notes payable – related party
Subscription agreement loans
Convertible notes
Total current liabilities
Forward purchase agreement liability
Total liabilities
Commitments and contingencies (Note 6)
Stockholders’ equity (deficit)
Series A convertible preferred stock, 30,000 and 0 shares as designated, respectively, $0.0001 par value; 17,050 and 0 shares issued or outstanding, respectively
Common stock; $0.0001 par value; 490,000,000 shares authorized; 1,295,234 and 117,780 issued and outstanding, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders’ equity (deficit)
Total liabilities and stockholders’ equity (deficit)
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Reverse stock split
Income Statement [Abstract]
Net revenue
Cost of revenue
Inventory write off
Gross margin
OPERATING EXPENSES
General and administrative (including stock based compensation of $157,500, $0, $157,500 and $14,131,250, respectively)
Research and development
Sales and marketing
Merger and acquisition expenses
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Interest expense
Change in fair value of derivative liabilities and convertible notes
Gain (loss) on extinguishment of debt
Total other expense, net
Loss before provision for income taxes
Income tax expense
Net loss
Weighted average shares outstanding of Common Stock, basic
Weighted average shares outstanding of Common Stock, diluted
Net loss per common share - basic
Net loss per common share - diluted
Stock based compensation
Balance
Balance, shares
Issuance of Series A Convertible Preferred Stock
Issuance of Series A Convertible Preferred Stock, shares
Conversion of convertible notes to Series A Convertible Preferred Stock
Conversion of convertible notes to Series A Convertible Preferred Stock, shares
Conversion of convertible notes to common stock
Conversion of convertible Notes, shares
Issuance of incentive shares pursuant to the January 2026 Share Purchase Agreement
Issuance of incentive shares pursuant to the January 2026 Share Purchase Agreement, shares
Issuance of commitment fee shares under ELOC agreement
Issuance of commitment fee shares under ELOC agreement, shares
Issuance of shares pursuant to debt exchange agreements
Issuance of shares pursuant to debt exchange agreements, shares
Net loss
Conversion of Series A Convertible Preferred Stock to common stock
Conversion of Series A Convertible Preferred Stock to common stock, shares
Shares issued for consulting services
Shares issued for consulting services, shares
Conversion of warrants
Conversion of warrants, shares
Issuance of shares in Reverse Recapitalization
Issuance of shares in Reverse Recapitalization, shares
Issuance of shares under working capital loans and non redemption agreements
Issuance of shares under working capital loans and non redemption agreements, shares
Stock based compensation
Stock based compensation, shares
Shares issued from debt extinguishment
Shares issued from debt extinguishment, shares
Balance
Balance, shares
Statement of Stockholders' Equity [Abstract]
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Adjustments to reconcile net loss to net cash flows used in operating activities:
Amortization of debt discount
Interest expense
(Gain) loss on extinguishment of debt
Change in fair value of derivative liabilities and convertible notes
Interest capitalized
Inventory write-off
Stock-based compensation expense
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Inventories
Accounts payable
Accrued expenses
Due from related party
Other current liabilities
Net cash flows used in operating activities
Cash flows from financing activities:
Issuance of Series A convertible preferred stock
Proceeds from Reverse Recapitalization
Proceeds from issuance of convertible notes
Deferred financing costs
Proceeds from debenture
Repayment of debenture
Proceeds from notes payable - related party
Repayment of notes payable – related party
Net cash flows provided by financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents, beginning of the period
Cash and cash equivalents, end of the period
Supplemental cash flow information:
Cash paid for interest
Supplemental disclosure of non-cash investing and financing activities:
Conversion of convertible notes to common stock
Issuance of incentive shares pursuant to the January 2026 Share Purchase Agreement
Issuance of shares pursuant to debt exchange agreements
Conversion of convertible notes to Series A convertible preferred stock
Conversion of Series A convertible preferred stock to common stock
Issuance of commitment fee shares under ELOC agreement
Due to affiliate write-off
Accounts payable and other liabilities combined, net
Promissory note fee - related party, write-off
Promissory note fee - related party, combined
Subscription agreement loans combined
Loan and transfer notes payable combined
Forward purchase agreement liability combined
Issuance of common stock for services
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Rule 10b5-1 Arrangement Modified
Non-Rule 10b5-1 Arrangement Modified
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Organization and Business
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Reverse Recapitalization
Reverse Recapitalization
Related Party Transactions [Abstract]
Related Party Transaction
Debt Disclosure [Abstract]
Convertible Notes
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Securities Purchase Agreement
Securities Purchase Agreement
Equity [Abstract]
Stockholders’ equity (deficit)
Fair Value Disclosures [Abstract]
Fair Value Measurements
Segment Reporting [Abstract]
Segments
Subsequent Events [Abstract]
Subsequent Events
Basis of Presentation
Cash, Cash Equivalents and Concentrations
Concentrations
Inventories
Recently Issued Accounting Pronouncements
Schedule of Total Revenues by Major Geographical Area
Schedule of Reconciles the Elements of the Business Combination
Schedule of Consummation of the Business Combination
Schedule of Number of Shares Conversion Ratio
Schedule of Note Issuance
Schedule of Assets and Liabilities That are Measured at Fair Value On a Recurring Basis
Schedule of Convertible Notes
Schedule of Fair Value of the Convertible Notes
Schedule of Models Used in Forward Purchase Agreements Liabilities
Schedule of Fair Value Forward Purchase Agreement Liabilities
Summary of Change in Fair Value of Derivative Liability
Schedule of Key Inputs of Models Used to Value Derivative Liability
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Working capital
cash and cash equivalents
Net loss
Accumulated deficit
Business combination proceeds
Proceeds from issuance of common stock
Business combination additional amount
Received net payout
Number of common stock
Payments for applicable fee
AccountingPoliciesTable [Table]
Total revenues
Cash equivalents
FDIC limit
Impaired due to obsolesce
Schedule Of Reconciles Elements Of Business Combination
Cash-trust and cash, net of redemptions
Less: transaction costs, paid
Net proceeds from the Reverse Recapitalization
Less: Accounts payable, Accrued liabilities and Other current liabilities combined
Less: Promissory note fee – related party combined
Less: Subscription agreement loans combined
Less: Loan and transfer notes payable combined
Less: Forward purchase agreement liability combined
Add: Other assets, net
Reverse Recapitalization, net
Schedule Of Consummation Of Business Combination
PowerUp Class A common stock, outstanding prior to the Reverse Recapitalization
Less: Redemption of PowerUp Class A common stock
Class A common stock of PowerUp
PowerUp Class B common stock, outstanding prior to the Reverse Recapitalization
Total Reverse Recapitalization Class A common stock, before giving effect to Reverse Splits (see Note 1. Description of Organization and Business)
Reverse Recapitalization Class A common stock, after giving effect to the Reverse Splits (see Note 1. Description of Organization and Business)
Issuance of shares related to working capital agreements
Aspire Biopharma, Inc. shares
Common Stock immediately after the Reverse Recapitalization, after giving effect to the Reverse Splits (see Note 1. Description of Organization and Business)
NumberOfSharesCoversionRatioTable [Table]
Number of Shares
Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]
Subsidiary, Sale of Stock [Line Items]
Business combination gross proceeds amount
Transaction costs
Number of warrants to purchase shares issued
Related Party Transaction [Table]
Related Party Transaction [Line Items]
Total
Liabilities
Debt
Loan and transfer notes payable
Sponsor contribution
Payments for loans
Debt incurred in interest expense
Debt interest and fees
Loan payable
Loans payable
Loss contingency, damages sought, value
Administrative fees expense
Debt interest rate
Principal amount
Gross proceeds
Debt interest stated percentage
Debt unamortized discount
Repayments of debt
Amortized debt discount
Short-Term Debt [Table]
Short-Term Debt [Line Items]
Original issue discount percentage
Aggregate principal amount
Conversion price per share
Conversion floor price per share
Commitment fee shares to investors
Repayment of convertible debt
Change in fair value of derivatives
Remaining debt converted into common stock, shares
Convertible Notes
Subscription price
Maturity date
Original issues discount
Convertible notes amount converted
Remaining debt converted into common stock, value
Subscription price
Gross proceeds
Common stock issued as incentive shares
Amortized debt discounts
CommitmentsAndContingenciesDisclosureTable [Table]
Warrants outstanding
Value of shares availbale for purchase
Shares issuable description
Number of shares issued
Additional payment of commitment fee shares
Assets acquired
Business acquistion description
Transaction costs
Purchase price and consideration description
Credit facility principal amount
Acquisition percentage
Upfront fee paid
Loss contingency, damages sought
Liability claim
Business Combination [Table]
Shares available for sale
Preferred stock, conversion term
Offering description
Temporary equity shares authorized
Temporary equity carrying amount
Total issuance of shares value
Issuance of shares related costs
Shares issued
Preferred Stock shares conversion
Stock, Class of Stock [Table]
Class of Stock [Line Items]
Exercise price of warrants
Public warrant exercisable term
Redemption price per public warrant
Redemption period
Warrant redemption condition minimum share price
Threshold trading days for redemption of public warrants
Threshold consecutive trading days for redemption of public warrants
Shares outstanding percentage
Shares issued to affiliated company
Business combination shares
General and administrative expenses
Number of warrants issued
Common stock issued upon warrant conversion
Debt conversion amount
Number of shares issued upon debt conversion
Exchange description
Fair Value, Recurring and Nonrecurring [Table]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets:
Money market funds
Liabilities:
Forward purchase agreement liabilities
Convertible notes
Derivative liability
Total liabilities
Fair Value Measurement Inputs and Valuation Techniques [Table]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Convertible notes measurement input
Fair Value, off-Balance-Sheet Risk [Table]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Convertible notes, beginning balance
Paid in kind interest
Change in fair value
Repayment of Convertible notes
Convertible notes, ending balance
Derivative liability measurement input
Balance
Change in fair value
Balance
Initial recognition derivative liability
Change in fair value derivative liability
Fair value derivative liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liability, beginning balance
Change in fair value
Derivative liability, ending balance
Derivative liability measurement input
Subsequent Event [Table]
Subsequent Event [Line Items]
Shares converted
Conversion price
Share issued on conversion
Purchase price
Deferred revenue
Aggregate purchase price
Original issue discount
Conversion price increased
Placement agency fee percentage
Non accountable expenses percentage
Management fee, description
Closing fee
Annual management fee
Transaction description
Warrants, each exercisable for one share of common stock
Common Stock, par value $0.0001 per share
Rule 10b5 1 Arr Modifieded Flag.
NonRule 10b5 1 Arr Modifieded Flag.
Subscription agreement loan.
Forward purchase agreement liability.
Promissory note fee.
Series A Convertible Preferred Stock [Member]
Conversion of convertible notes to convertible preferred stock.
Stock issued during period value under purchase agreement.
Stock issued during period value issuance of commitment fee shares undereloc agreement
Stock issued during period value debt exchange.
Conversion of convertible notes to convertible preferred stock shares.
Stock issued during period shares under purchase agreement.
Stock issued during period shares issuance of commitment fee share under ELOC agreement.
Stock issued during period shares debt exchange.
Conversion of series convertible preferred stock to common stock.
Conversion of series convertible preferred stock to common stock shares.
Stock issued during period shares issuance of shares in reverse recapitalization.
Stock issued during period value issuance of shares in reverse recapitalization.
Stock issued during period shares shares issued from debt extinguishment.
Stock issued during period value issued from debt extinguishment.
Issuance of incentive shares pursuant to january 2026 share purchase agreement.
Issuance of shares pursuant to debt exchange agreements.
Accounts payable and other liabilities combined net.
Promissory Note fee – related party combined.
Subscription agreement loans combined.
Forward purchase agreement liability combined.
Conversion of convertible notes to series convertible preferred stock.
Issuance of commitment fee shares under ELOC agreement.
Loan and transfer notes payable combined.
Issuance of common stock for services.
Working capital deficit.
Net cash received in business combination
Securities Purchase Agreement [Member]
Proceeds from issuance of convertible securities.
Purchase Agreement [Member]
Payments for applicable fee.
International [Member]
Recapitalization [Disclouser Text Block]
Business combination gross proceeds amount.
Business recapitalization cost of acquired entity transaction costs amount.
Reconciles the Elements of the Business Combination [Table Text Block]
Business acquisition cost of acquired entity transaction costs amount.
Business recapitalization cost of acquired entity transaction costs proceeds.
Accounts payable accrued liabilities and other current liabilities combined.
Loan and transfer note payable combined.
Business combination other net.
Reverse recapitalization net.
Consummation of The Business Combination [Table Text Block]
Business combination power up class common stock outstanding prior to business combination.
Business combination redemption of powerup class common stock.
Business combination class common stock of powerup.
Business combination powerup class b common stock outstanding prior to business combination.
Reverse recapitalization class common stock before reverse split
Reverse recapitalization class common stock after reverse split
Business combination issuance of shares related working capital agreements.
Business combination aspire biopharma inc shares.
Common stock immediately after reverse recapitalization.
Schedule of Number of Shares And Conversion Ratio [Table Text Block]
Class of Stock [Axis]
Common Stock Issued to Existing Aspire Biopharma Inc Shareholders [Member]
Common Stock Obligation Shares Issued [Member]
Conversion Ratio [Member]
Loan and Transfer Agreement [Member]
Sponsor and Ssvk Associates Llc [Member]
Apogee Pharma [Member]
Jinal Sheth [Member]
Second Loan And Transfer Agreementt [Member]
Apogee Pharma Two [Member]
First Subscription Agreement [Member]
Second Subscription Agreements [Member]
First and Second Subscription Agreement [Member]
Debt incurred in interest expense.
Debt interest and fees.
Modified Promissory Note Fee Agreement [Member]
Affiliates [Member]
September Twenty Seven Two Thousand Twenty Four [Member]
December Thirty First Two Thousand Twenty Four [Member]
Cobra Alternative Capital Strategies LLC [Member]
Change in fair value of derivative liabilities.
August Securities Purchase Agreement [Member]
August 2025 Notes [Member]
Subscription price.
First Tranche [Member]
Second Tranche [Member]
Third Tranche [Member]
August 2025 Securities Purchase Agreement [Member]
Debentures [Member]
Represents information pertaining to a redeemable warrant (Private Placement Warrant) that entitles the holder to purchase shares of common stock if the underwriter's option is exercised in full.
Second ELOC Agreement [Member]
Arena Business Solutions Global SPC II Ltd [Member]
Additional payment of commitment fee shares
Instaprin Pharmaceuticals Inc [Member]
Purchase price and consideration description.
Aspire Credit Facility [Member]
Upfront fee paid.
Driver Controls Systems Business Unit [Member]
Securities Purchase Agreement [Table Text Block]
Public Warrants [Member]
Redemption price per share or per unit of warrants or rights outstanding.
Redemption period.
The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant.
Threshold number of specified trading days for stock price trigger considered for redemption of warrants.
Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.
Corporate Advisory Agreement [Member]
Aspire Biopharma Warrants [Member]
Settlement Agreement [Member]
Convertible Notes [Member]
Share Purchase Agreement [Member]
Exchange Agreements [Member]
Schedule of Convertible Notes [Table Text Block]
Change in fair value convertible notes.
Schedule of Fair Value of Convertible Notes [Table Text Block]
Fair Value Assets and Liabilities Measured on Forward Purchase Agreement Liabilities Valuation Techniques [Table Text Block]
Measurement Input Likelihood [Member]
Schedule of Fair Value of Forward Purchase Agreement Liabilities [Table Text Block]
Change in fair value derivative liability.
Initial recognition derivative liability.
Inventory write off.
Conversion floor price per share.
Chief Executive [Member]
Sponsor [Member]
Due to affiliate write-off.
Promissory note fee - related party, write-off.
Note Purchase Agreement [Member]
Placement agency fee percentage
Nonaccountable expenses percentage
Management Services Agreement [Member]
Closing fee
Class of Stock [Axis] [Default Label]
Assets, Current
Assets [Default Label]
Liabilities, Current
Equity, Attributable to Parent
Liabilities and Equity
Gross Profit
Operating Expenses
Operating Income (Loss)
Interest Expense, Nonoperating
Nonoperating Income (Expense)
Income Tax Expense (Benefit)
Shares, Outstanding
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Inventories
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Accrued Liabilities
Increase (Decrease) in Due from Related Parties
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments of Debt Issuance Costs
Repayments of Bank Debt
Repayments of Notes Payable
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Conversion of Stock, Amount Converted
IssuanceOfIncentiveSharesPursuantToJanuary2026SharePurchaseAgreement
IssuanceOfSharesPursuantToDebtExchangeAgreements
IssuanceOfCommitmentFeeSharesUnderElocAgreement
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Recapitalization [Disclouser Text Block]
SecuritiesPurchaseAgreementDisclosureTextBlock
Equity [Text Block]
Inventory, Policy [Policy Text Block]
BusinessRecapitalizationCostOfAcquiredEntityTransactionCostsProceeds
AccountsPayableAccruedLiabilitiesAndOtherCurrentLiabilitiesCombined
LoanAndTransferNotePayableCombined
BusinessCombinationOtherNet
ReverseRecapitalizationNet
BusinessCombinationClassCommonStockOfPowerup
ReverseRecapitalizationClassCommonStockBeforeReverseSplit
ReverseRecapitalizationClassCommonStockAfterReverseSplit
CommonStockImmediatelyAfterReverseRecapitalization
BusinessRecapitalizationCostOfAcquiredEntityTransactionCostsAmount
Debt, Current
Convertible Debt, Fair Value Disclosures
Derivative Liability
Equity, Fair Value Disclosure
Liabilities, Fair Value Adjustment
Derivative Liability, Measurement Input